The acquisition significantly enriches GammaDelta Therapeutics’ novel platform based on tissue-derived gamma delta T cells. The complementary technologies have potential in the development of new immunotherapies aimed at treating a broad range of cancers, from haematological malignancies to solid tumours.
“This transaction is a landmark for the Portuguese Biotech sector and I am confident GammaDelta Therapeutics is the right partner to help bringing our DOT-Cells technology to patients. We are taking a decisive step in confirming the scientific innovation of biomedical research conducted in Portugal and also providing a clear signal the Portuguese entrepreneurial world is aware of such potential in the life sciences sector and is actually able to develop it”, says Diogo Remechido Anjos, co-Founder and former Chairman and CEO of Lymphact adding “this would not be possible without an incredible team”.
“Gamma Delta Therapeutics has proprietary technology that is highly complementary to our DOT-Cells; therefore, the potential for synergies is immense. We are also very excited to have access to the exceptional resources and team of GDT to support bringing DOT-Cells to the clinic”, noted Bruno Silva-Santos, the leading scientist behind Lymphact.
Paolo Paoletti, CEO of GammaDelta Therapeutics, said: “We are excited about the potential of Lymphact’s technology and believe that it complements GammaDelta Therapeutic’s T cell expertise and will help advance our mission to deliver new treatments for cancer patients using Vδ1 gamma delta T cells.”
Portugal Ventures’s CEO, Rita Marques, commented that “with this transaction, we are promoting Portugal to the world by exporting national knowledge and technology, with relevant socio-economic impact. We believe that this success story will leverage other cases in the future, and we will witness a multiplying effect of Life and Health Sciences projects that will continue to arouse the interest of international players in technological innovation originated in Portugal.”
For Busy Angels, chairman Luís Mira Amaral added “this acquisition fuels our initial dream of being able to support such an impactful technology, researched and developed in Portugal, to reach cancer patients worldwide.”